This stock is under the usual year end tax-loss selling pressure, so it should see a nice bounce in early Jan. The only problem I see with their technology is that another more feasable and recently more promising technolgy called Naked DNA introduction spearheaded by a company called ISIS Pharmaceuticals (ISIP) will be challenging competition.
Try visiting Amylin's home page. It's fairly good and will give you a good idea of their research. If that doesn't satisfy you then send for their annual report. Of course their lead drug which is a synthetic form of the protein Amylin is the main source of investor interest. There was an excellent article (about 3 pages long) featuring Amylin's prospects. It was in Barron's about in the middle part of November. However, I think this sstock is trailing its bottom, it could go a little lower but not much in the short term. Be cautious because they still need to fund research studies out to 2000. Support will return when they post positive results in the next examination of continuing stage III results now that they are controlling for the variance in Insulin usage. Afterall this is where they got themselves in hot water, but if they can rebuild confidence and someday get this drug on the market, it'll be a huge blockbuster! Just read the article and do some research.
Forest Labs should do very well next year. Look for new 52 wk highs, based on improving margins of existing products, the introduction of Synaptin (once approved), and greater excitement for their next big antidepressant drug which will compete with prosac and other SSRI (selective seritonin reuptake inhibitors) drugs. Synaptin, which is under FDA approval now, should be a huge contributor to the bottom line. It'll be the only drug approved for Alztimers that works at the level of AcH receptors, which are believed to play an important role in the function of neurons, esp. those in the brain.